From what I've read about opiate analogues, whatever thc analogues they're using ~15 years after the Huffman paper are far removed from their original state.
I can also confirm there is a tremendous demand for thc carts in non-legal states.
From what I've read about opiate analogues, whatever thc analogues they're using ~15 years after the Huffman paper are far removed from their original state.
I can also confirm there is a tremendous demand for thc carts in non-legal states.
I have medical so thankfully I don't need to mess with the black market at this point. I would _highly_ advise against using any synthetic cannabinoids.
Any specific reasons to say this? Medical knowledge, personal experience or other?
I did have one experience with a synthetic cannabinoid and it was very bad indeed, took me days to recover. FYI. I'd not rule out trying it again but with great care. Though now it's illegal in the UK, so prob won't happen.
AMB-FUBINACA caused a "zombie outbreak" which sent 33 people to the hospital in Brooklyn: https://www.nytimes.com/2016/12/14/nyregion/zombielike-state...
Anecdotally, AM-2201 seems to cause enlarged liver and other health problems with long-term use: https://www.erowid.org/experiences/exp.php?ID=95702
I remember CP-55,940 and WIN-55,212 having serious side effects but I couldn't find information..
They've lead to seizures and have been linked to at least a few deaths.
>Studies have found that these compounds tend to activate the CB1 receptor to a greater degree than does THC, suggesting that synthetic marijuana compounds have the ability to induce far more intense effects than marijuana, according to the review.
https://www.livescience.com/57747-synthetic-marijuana-risks....
>Much of our understanding of cannabinoid tolerance, dependence and withdrawal has been based on studies involving Δ9-THC, a relatively weak partial agonist at CB1 and CB2 receptors. However, the SCBs commonly found in quasi-legal commercial products such as K2 and Spice are typically full cannabinoid receptor agonists. Importantly, a drug's efficacy determines how “powerful” its maximal effects may be in biological systems. A low efficacy cannabinoid like Δ9-THC will have a less pronounced maximal effect than a higher efficacy cannabinoid, such as the SCBs present in commercial products, and this difference in maximal effects cannot be overcome simply by increasing the dose of Δ9-THC. In other words, no amount of Δ9-THC can stimulate cannabinoid receptors to the same degree as the SCBs currently emerging as drugs of abuse. This has left researchers working with these high efficacy SCBs in the unusual position of having to determine whether their effects are related to the unprecedented degree of cannabinoid receptor stimulation elicited by these compounds, or whether they are produced by interactions with other, non-cannabinoid receptor systems.